Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299675 · ClinicalTrials.gov registry record
SureScan Post-Approval Study
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 2,483
- Enrollment target
NCT01299675: Completed study, sponsored by Medtronic.
NCT01299675 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 2,483 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01299675 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 2,483 participants
- Enrollment target
Study Summary
The purpose of this Post-Approval Study (PAS) is to demonstrate the chronic performance of the SureScan pacing system when used in an MRI environment according to product labeling. This study is required by the Food and Drug Administration (FDA) as a condition of product approval.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,483 participants |
| Start Date | 2011-02-08 |
| Est. Completion | 2017-10-02 |
What the finished NCT01299675 record still lists
NCT01299675 is an observational study that tracks outcomes without assigning an intervention. Its 2,483 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01299675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01299675 about?
NCT01299675 is a clinical study titled "SureScan Post-Approval Study". The purpose of this Post-Approval Study (PAS) is to demonstrate the chronic performance of the SureScan pacing system when used in an MRI environment according to product labeling. This study is required by the Food and Drug Administration (FDA) as a condition of product approval.
What is the current status of trial NCT01299675?
This trial is currently completed. The enrollment target is 2,483 participants. The study started on 2011-02-08. Estimated completion is 2017-10-02.
Who is sponsoring clinical trial NCT01299675?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI